AstraZeneca and Sun Pharma collaborate to widen SZC access across India, boosting hyperkalaemia care through marketing capabilities and distribution strengths.

• The agreement enables both companies to promote, market, and distribute SZC under separate brand names while AstraZeneca maintains regulatory responsibilities.
• Hyperkalaemia significantly impacts chronic kidney disease and heart failure patients receiving RAAS inhibitors, with prevalence reaching half of the affected populations.
• The partnership supports broader patient access to innovative therapy and aligns with efforts to improve outcomes and address hyperkalaemia burden.